uniQure(QURE) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Revenue for the year ended December 31, 2025, was $16.1 million, a decrease from $27.1 million in 2024, primarily due to a $10.7 million decrease in collaboration revenue and a $6.1 million decrease in contract manufacturing revenues, offset by a $5.8 million increase in license revenues [24] - Research and development expenses were $140.7 million for 2025, down from $143.8 million in 2024, driven by a $26 million decrease in total other research and development expenses [25][26] - Cash, cash equivalents, and investment securities totaled $622.5 million as of December 31, 2025, compared to $367.5 million as of December 31, 2024, primarily due to proceeds of approximately $404.2 million raised from public offerings [28] Business Line Data and Key Metrics Changes - AMT-130 showed a statistically significant 75% slowing of disease progression in Huntington's disease as measured by the Composite Unified Huntington's Disease Rating Scale, and a 60% slowing as measured by Total Functional Capacity [5] - AMT-191 for Fabry disease reported that all 11 patients in the Phase 1/2 trial exhibited elevated alpha-Gal A enzyme activity, with 6 patients successfully withdrawn from enzyme replacement therapy [16] - AMT-260 for mesial temporal lobe epilepsy showed promising initial data with a reduction in seizure frequency over the first 6 months, with no serious adverse events reported [18] Market Data and Key Metrics Changes - The company is actively assessing ex-U.S. opportunities, evaluating priority markets based on epidemiology, regulatory pathways, pricing, and reimbursement landscapes [21] - The potential market for AMT-191 in Fabry disease is positioned to compete against chronic enzyme replacement therapies, highlighting the advantages of a one-time gene therapy approach [22] Company Strategy and Development Direction - The company remains focused on engaging with regulatory authorities to define the most appropriate path forward for AMT-130, while advancing pipeline programs with discipline [29] - The strategy includes pursuing named patient and early access program opportunities in rare diseases outside the U.S. to enable access to therapies ahead of formal reimbursement decisions [21] - The company aims to leverage the Enroll-HD database to strengthen study designs for Phase 3 trials and minimize patient burden [45] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength and durability of AMT-130 data, emphasizing the urgency of unmet needs in the Huntington's disease community [29] - The company is committed to constructive engagement with the FDA to explore regulatory flexibility for rare diseases, particularly in light of the challenges faced in the approval process [7][10] Other Important Information - The company plans to request a Type B meeting in the second quarter of 2026 to discuss potential Phase 3 study design approaches [14] - The company has initiated regulatory discussions with several agencies outside the U.S. following unsolicited outreach after the 3-year data disclosure [14] Q&A Session Summary Question: Are there any paths to push your agenda beyond traditional FDA channels? - The company is exploring opportunities outside the U.S. and believes that advocacy from the patient community is critical in educating elements outside the FDA about the urgency of the situation [33] Question: Can you confirm the plan for the four-year data submission? - The company plans to amend the protocol to include a four-year analysis and will present data from all patients who have reached three years, along with the 12 patients at four years [35] Question: What is the strategy for the Type B meeting? - The main goal is to discuss designs for the Phase 3 trial, leveraging the Enroll-HD database to strengthen study designs and minimize patient burden [44] Question: What are the sticking points with the FDA regarding the sham control requirement? - The FDA has raised concerns about the absence of treatment effects relative to sham subjects in the U.S. Phase I/II study after 12 months, leading to the recommendation for a sham-controlled study [10][70] Question: Is the company committed to moving forward with a sham study? - The company is dedicated to pursuing AMT-130 and will consider the feasibility and ethical implications of a sham-controlled study based on patient community support [78]